Part-Time
Arzt
CSL
10,001+ employees
Develops and delivers biotherapies and vaccines
No salary listed
Bellheim, Germany
In Person
On-site role in Karlsruhe, Germany; part-time options available.
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to CSL
See people who can refer or advise you
- Approbation as a physician (Arzt/Ärztin)
- Demonstrated sense of responsibility and willingness to commit; ability to work well in a team
- Engagement, communication skills, and a customer-oriented, open and goal-oriented work style
- Carry out donor suitability assessments
- Inform potential donors about plasmapheresis and possible health risks
- Provide medical supervision during plasmapheresis
- Experience in handling IT/EDV is desirable
- Interest in returning to work after a career break or part-time employment seeking individuals (career reentry or part-time opportunities)
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
- CSL completed $176 million in FY26 cost savings, ahead of plan.
- VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.
What critics are saying
- FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
- China albumin sales dropped 17% in FY26 after government cost-containment measures.
- Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.
What makes CSL unique
- CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
- HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
- CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.
CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.
Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.
In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...